User:Mr. Ibrahem/Infigratinib

Infigratinib, sold under the brand name Truseltiq, is a medication used to treat cholangiocarcinoma (bile duct cancer). Specifically it is used for advanced disease with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement that has failed other treatments. It is taken by mouth.

Common side effects include finger nail problems, mouth inflammation, dry eyes, tiredness, hair loss, joint pain, constipation, abdominal pain, and eye problems. Common lab abnormalities include kidney problems, low phosphate, high calcium, low potassium, and low sodium. Use in pregnancy may harm the baby. It is a kinase inhibitor of fibroblast growth factor receptors FGFR1, FGFR2 and FGFR3.

Infigratinib was approved for medical use in the United States in 2021. As of 2022 it is not approved in the United Kingdom or Europe, though has orphan status. In the United States it costs about 10,700 USD per 4 week cycle.